

Intravitreal (IVT) Injectable Market 2026

<https://marketpublishers.com/r/I20336F149F1EN.html>

Date: November 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: I20336F149F1EN

Abstracts

The Intravitreal (IVT) Injectable Market was valued at in and is anticipated to reach by , at a CAGR of 0.058 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Intravitreal (IVT) Injectable Market.

This report delivers a comprehensive overview of the Intravitreal (IVT) Injectable Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Intravitreal (IVT) Injectable Market. The Intravitreal (IVT) Injectable Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Intravitreal (IVT) Injectable Market Scope:

By Drug Class

Anti-VEGF

Steroids

Antibiotics

Antifungals

Antivirals

By Indication

Diabetic Retinopathy

Macular Degeneration

Endophthalmitis

Retinal Vein Occlusions

Others

By Distribution Channel

Hospital pharmacies

Retail pharmacies

Online pharmacies

Others

Key Players

F. Hoffmann-La Roche Ltd.

Regeneron Pharmaceuticals, Inc.

Alcon Pharmaceuticals

Valeant Pharmaceuticals International, Inc.

Novartis AG

Allergan

Alimera Sciences

ThromboGenics, Inc.

Bristol-Myers Squibb Company

Bausch & Lomb(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Intravitreal (IVT) Injectable Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Intravitreal (IVT) Injectable Market. The Intravitreal (IVT) Injectable Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering

in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1. The increasing prevalence of cataracts worldwide is expected to drive market growth.

4.1.2. Restraints:

4.1.2.1. Risks associated with the Intravitreal injections are expected to hamper the market growth.

4.1.3. Opportunity

4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces

5.2. Supply Chain

5.3. Pricing Analysis

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market

6.1.1. Before COVID-19 Market Scenario

6.1.2. Present COVID-19 Market Scenario

6.1.3. After COVID-19 or Future Scenario

6.2. Pricing Dynamics Amid Covid-19

6.3. Demand-Supply Spectrum

6.4. Government Initiatives Related to the Market During Pandemic

6.5. Manufacturers Strategic Initiatives

6.6. Conclusion

7. BY DRUG CLASS

7.1. Introduction

7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

7.1.2. Market Attractiveness Index, By Drug Class

7.2. Anti-VEGF*

7.2.1. Bevacizumab (Avastin)

7.2.2. Introduction

7.2.3. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

7.2.4. Ranibizumab (Lucentis)

7.2.5. Aflibercept (Eylea)

7.2.6. Brolucizumab (Beovu)

7.2.7. Faricimab (Vabysmo)

7.2.8. Others

7.3. Steroids

7.3.1. Triamcinolone acetonide (Kenalog)

7.3.2. OZURDEX (dexamethasone)

7.3.3. Others

7.4. Antibiotics

7.4.1. Meropenem

7.4.2. Linezolid

7.4.3. Moxifloxacin

7.4.4. Vancomycin

7.4.5. Cefazoline

7.4.6. Ceftriaxone

7.4.7. Ceftazidime

7.4.8. Clindamycin

7.4.9. Others

7.5. Antifungals

7.5.1. Voriconazole

7.5.2. Amphotericin B

7.6. Antivirals

7.6.1. Ganciclovir

7.6.2. Foscarnet

7.6.3. Cidofovir

7.6.4. Others

8. BY INDICATION

8.1. Introduction

8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

8.1.2. Market Attractiveness Index, By Indication

8.2. Diabetic Retinopathy*

8.2.1. Introduction

8.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

8.3. Macular Degeneration

8.4. Endophthalmitis

8.5. Retinal Vein Occlusions

8.6. Others

9. BY DISTRIBUTION CHANNEL

9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9.1.2. Market Attractiveness Index, By Distribution Channel

9.2. Hospital pharmacies*

9.2.1.1. Introduction

9.2.1.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

9.3. Retail pharmacies

9.4. Online pharmacies

9.5. Others

10. BY REGION

10.1. Introduction

10.1.1. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.2.6.1. U.S.
 - 10.2.6.2. Canada
 - 10.2.6.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics
 - 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
 - 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.3.6.1. Germany
 - 10.3.6.2. U.K.
 - 10.3.6.3. France
 - 10.3.6.4. Italy
 - 10.3.6.5. Spain
 - 10.3.6.6. Rest of Europe
- 10.4. South America
 - 10.4.1. Introduction
 - 10.4.2. Key Region-Specific Dynamics
 - 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
 - 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.4.6.1. Brazil
 - 10.4.6.2. Argentina
 - 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
 - 10.5.1. Introduction
 - 10.5.2. Key Region-Specific Dynamics
 - 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
 - 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.5.6.1. China
 - 10.5.6.2. India
 - 10.5.6.3. Japan
 - 10.5.6.4. Australia

10.5.6.5. Rest of Asia Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario

11.2. Market Positioning/Share Analysis

11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

12.1. F. Hoffmann-La Roche Ltd.*

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Key Highlights

12.1.4. Financial Overview

12.2. Regeneron Pharmaceuticals, Inc.

12.3. Alcon Pharmaceuticals

12.4. Valeant Pharmaceuticals International, Inc.

12.5. Novartis AG

12.6. Allergan

12.7. Alimera Sciences

12.8. ThromboGenics, Inc.

12.9. Bristol-Myers Squibb Company

12.10. Bausch & Lomb(*LIST NOT EXHAUSTIVE)

13. DATAM INTELLIGENCE

13.1. Appendix

13.2. About Us and Applications

13.3. Contact Us

I would like to order

Product name: Intravitreal (IVT) Injectable Market 2026

Product link: <https://marketpublishers.com/r/l20336F149F1EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l20336F149F1EN.html>